Assertio Holdings, Inc.

NasdaqCM:ASRT Stock Report

Market Cap: US$91.3m

Assertio Holdings Future Growth

Future criteria checks 0/6

Assertio Holdings's revenue is forecast to decline at 4.5% per annum while its annual earnings are expected to grow at 155.2% per year. EPS is expected to grow by 156.3% per annum.

Key information

155.2%

Earnings growth rate

156.3%

EPS growth rate

Pharmaceuticals earnings growth24.1%
Revenue growth rate-4.5%
Future return on equityn/a
Analyst coverage

Low

Last updated07 May 2024

Recent future growth updates

Recent updates

Assertio Holdings, Inc. (NASDAQ:ASRT) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

May 07
Assertio Holdings, Inc. (NASDAQ:ASRT) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Does Assertio Holdings (NASDAQ:ASRT) Have A Healthy Balance Sheet?

Apr 18
Does Assertio Holdings (NASDAQ:ASRT) Have A Healthy Balance Sheet?

Improved Revenues Required Before Assertio Holdings, Inc. (NASDAQ:ASRT) Stock's 26% Jump Looks Justified

Mar 13
Improved Revenues Required Before Assertio Holdings, Inc. (NASDAQ:ASRT) Stock's 26% Jump Looks Justified

We Think Assertio Holdings (NASDAQ:ASRT) Can Stay On Top Of Its Debt

Apr 26
We Think Assertio Holdings (NASDAQ:ASRT) Can Stay On Top Of Its Debt

Is There An Opportunity With Assertio Holdings, Inc.'s (NASDAQ:ASRT) 23% Undervaluation?

Mar 02
Is There An Opportunity With Assertio Holdings, Inc.'s (NASDAQ:ASRT) 23% Undervaluation?

Assertio Holdings Looks Good To Rebound After Recent Price Plunge

Sep 07

Assertio Holdings: Substantial Upside

Aug 21

Assertio Therapeutics Q2 2022 Earnings Preview

Aug 05

Assertio Holdings: Management Still Swimming Against The Tide

Jun 10

Assertio's Phenomenal Turnaround

May 19

Assertio Holdings: Recent Breakout To Lead To Sustained Gains

Apr 07

Assertio's Digital Strategy Looks To Be Paying Off

Jan 21

Assertio shares rise on Q1 revenue strength, provides FY forecast

May 07

Assertio announces restructuring plan and leadership change

Dec 15

Assertio Therapeutics EPS misses by $0.05, beats on revenue

Nov 06

Earnings and Revenue Growth Forecasts

NasdaqCM:ASRT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2025130231332
12/31/2024120-1715172
3/31/2024142-3333334N/A
12/31/2023152-3324950N/A
9/30/2023169-1864471N/A
6/30/2023168985178N/A
3/31/2023162973274N/A
12/31/20221561103679N/A
9/30/2022139262156N/A
6/30/2022130251651N/A
3/31/202212131837N/A
12/31/2021111-1-136N/A
9/30/2021110-30-5-5N/A
6/30/2021119-44-24-24N/A
3/31/2021114-65-44-45N/A
12/31/2020108-28303-66N/A
9/30/2020135-196317-52N/A
6/30/2020156-183365-3N/A
3/31/2020192-16240538N/A
12/31/2019230-2178990N/A
9/30/2019157-499598N/A
6/30/2019180-4130135N/A
3/31/2019186-11121127N/A
12/31/2018256376772N/A
9/30/2018364288084N/A
6/30/2018381-36910N/A
3/31/2018419-421919N/A
12/31/2017381-102N/A62N/A
9/30/2017410-114N/A76N/A
6/30/2017425-111N/A96N/A
3/31/2017442-95N/A103N/A
12/31/2016456-89N/A71N/A
9/30/2016443-75N/A88N/A
6/30/2016437-74N/A120N/A
3/31/2016415-85N/A130N/A
12/31/2015343-76N/A152N/A
9/30/201542650N/A89N/A
6/30/201537368N/A40N/A
3/31/2015346102N/A7N/A
12/31/2014390132N/A-56N/A
9/30/201423679N/A-60N/A
6/30/201422279N/A-45N/A
3/31/201418567N/A-51N/A
12/31/201313443N/A10N/A
9/30/2013120-2N/A5N/A
6/30/2013116-10N/A-10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ASRT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ASRT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ASRT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ASRT's revenue is expected to decline over the next 3 years (-4.5% per year).

High Growth Revenue: ASRT's revenue is forecast to decline over the next 3 years (-4.5% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ASRT's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.